VANCOUVER, British Columbia and BOSTON — December 3, 2025 — Leads & Copy — Xenon Pharmaceuticals Inc. (Nasdaq: XENE) will host an investor webinar to discuss data presentations at the American Epilepsy Society Annual Meeting (AES 2025).
The webinar will focus on new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real-world study data on the impact of depression and the burden of titration in epilepsy.
Additionally, the company will provide an update on its progress in preparing for the commercialization of azetukalner.
The webinar, titled “Azetukalner and Epilepsy Data Update: AES 2025,” is scheduled for Wednesday, December 10, 2025, from 10:00-11:00 AM Eastern Time.
Questions can be submitted via the chat function during the live webinar or in advance via email to investors@xenon-pharma.com.
More information on Xenon’s AES 2025 presentations can be found on Xenon’s website. A live webcast of the webinar will be available in the “Investors” section of Xenon’s website and posted for replay following the event. The date and time are subject to change.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics.
Azetukalner, Xenon’s lead molecule, is in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for potential pain treatment. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Colleen Alabiso, Senior Vice President, Corporate Affairs, can be contacted at (617) 671-9238. For media inquiries, email media@xenon-pharma.com. For investor inquiries, email investors@xenon-pharma.com.
Safe Harbor Statement: This press release contains forward-looking statements regarding clinical studies, efficacy, safety, development plans, addressable market, regulatory success, and commercial potential. These statements are based on current assumptions involving risks and uncertainties that could cause actual results to differ. Risks include clinical study outcomes, regulatory approvals, market conditions, competition, and economic factors. Xenon assumes no obligation to update these statements.
Source: Xenon Pharmaceuticals Inc.
